文献速递乳腺癌放疗

局部晚期乳腺癌新辅助放疗后的病理完全缓解与肿瘤学结局:澳大利亚视角

Pathologic Complete Response and Oncologic Outcomes in Locally Advanced Breast Cancers Treated With Neoadjuvant Radiation Therapy: An Australian Perspective.
PubMed 文献 · Pract Radiat Oncol · 2023-01-01

该回顾性多机构综述纳入2014年1月至2021年2月间接受新辅助放疗的138例临床分期患者共140例乳腺癌,评估病理完全缓解率、术后手术并发症率及肿瘤学结局。病理完全缓解率按Chevallier分类为36.4%、按Miller-Payne评分为42.1%,HER2阳性与三阴性表型缓解率更高。3年随访时局部区域无复发生存率98.1%、无远处转移生存率83.6%、总生存率95.3%。

要点

  • 新辅助放疗后病理完全缓解率按Chevallier分类为36.4%、按Miller-Payne评分为42.1%。
  • HER2阳性与三阴性表型的病理完全缓解率更高,分别为73.8%-85.7%与47.6%-57.1%。
  • 3年局部区域无复发生存率98.1%、无远处转移生存率83.6%、总生存率95.3%。

核心结论

  • 新辅助放疗有助于实现单期乳房切除与即刻自体乳房重建,术后并发症率与标准治疗相当,病理完全缓解率高并转化为较高的局部控制率、无远处转移生存率与总生存率。

研究设计与样本

  • 回顾性多机构综述,纳入2014年1月至2021年2月间138例临床分期患者共140例乳腺癌,均接受序贯新辅助化疗与新辅助放疗后行乳房切除伴或不伴腋窝手术及即刻自体乳房重建。

主要发现

  • 中位年龄47岁(四分位距42-52),中位随访35.2个月(四分位距17.1-46.5)。
  • 病理完全缓解率按Chevallier分类为36.4%、按Miller-Payne评分为42.1%。
  • HER2阳性表型病理完全缓解率为73.8%-85.7%,三阴性表型为47.6%-57.1%。
  • 发生21例3级手术并发症,包括10例3B级乳房事件与8例3B级供区事件,需手术再干预。
  • 3年随访时局部区域无复发生存率98.1%、无远处转移生存率83.6%、总生存率95.3%。

关键数值与推荐

  • 病理完全缓解分别按Chevallier分类与Miller-Payne评分定义并报告。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the degree of pathologic complete response (pCR), postoperative surgical complication rates, and oncological outcomes in women with locally advanced breast cancer or high-risk breast cancers treated with neoadjuvant radiation therapy (NART). METHODS AND MATERIALS: This retrospective, multi-institutional review involved 138 clinically staged patients with 140 breast cancers treated with NART between January 2014 and February 2021. Treatments involved sequential neoadjuvant chemotherapy and NART, followed by mastectomy with or without axillary surgery and immediate autologous breast reconstruction. Descriptive statistics were used to assess patient and disease features, treatment regimens, pathologic response, and factors affecting postoperative complications. Kaplan-Meier curves were performed to assess locoregional recurrence-free, distant metastasis-free, and overall survival outcomes. RESULTS: Median age was 47 years (interquartile range, 42-52). The median follow-up was 35.2 months (interquartile range, 17.1-46.5). pCR was achieved in 36.4% (as defined by Chevallier classification) or 42.1% (as defined by Miller-Payne scores) of patients. Greater pCR rates were achieved for HER2+ (73.8%-85.7%) and triple-negative phenotypes (47.6%-57.1%). There were 21 grade 3 surgical complications including 10 grade 3B breast events and 8 grade 3B donor-site events, where surgical reintervention was required. At 3-years' follow-up, the locoregional recurrence-free survival was 98.1%, distant metastasis-free survival was 83.6%, and overall survival was 95.3%%. CONCLUSIONS: NART is feasible to facilitate a single-stage mastectomy and immediate autologous breast reconstruction. This study demonstrated comparable rates of postoperative complication to standard of care, and high rates of pCR, which translates to high rates of locoregional control, distant metastasis-free survival, and overall survival.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lin YH, Chidley P, Admojo L, et al. Pathologic Complete Response and Oncologic Outcomes in Locally Advanced Breast Cancers Treated With Neoadjuvant Radiation Therapy: An Australian Perspective. Pract Radiat Oncol. 2023. PMID: 36599393. doi:10.1016/j.prro.2022.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。